Free genetic testing, offered partially or fully subsidized by industry, may have trade-offs, and health systems in Canada must carefully weigh potential clinical, ethical, and legal considerations to protect patient data, authors argue in a Canadian Medical Association Journal commentary. “Near- and long-term expansion in no-cost testing and industry partnership in genetics, with patient data as the commodity, is likely,” writes Kirsten Bartels, a genetic counselor at Providence Health Care Heart Centre, St. Paul’s Hospital, Vancouver, British Columbia, with co-authors. “Commodification of data is not the norm in health care systems in Canada and should not be introduced without due Read More
No comments:
Post a Comment